Retifanlimab is a humanized PD-L1 inhibitor that has been studied in Phase 3 trials for endometrial cancer, non-small cell lung cancer, and gastric and esophageal cancer, with orphan drug status for Merkle cell carcinoma and anal carcinoma. The gene discussed is CD274; the disease is non-small cell lung carcinoma.